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ABSTRACT  
Objective: To determine the drug utilization pattern of anti-diabetic medications in diabetic patients at diabetic outpatient clinics.  
Methods: A prospective observational study was conducted to find out the drugs utilization and prescriptions pattern of antihyperglycemic agents 
in diabetic outpatients in urban Telangana. This study was conducted for a period of six months, known cases of Diabetic Mellitus who were 
receiving antihyperglycemic medicines as outpatients of either sex of all age groups were included and Patients with gestational diabetes were 
excluded from the study. 
Results: In this study a total number of 250 prescriptions were collected which contained 1674 drugs. Among the prescriptions as an average each 
prescription contained more than 6.7drugs, this indicates polypharmacy. Among the antidiabetic drugs, metformin was found in a maximum 
number of prescription i.e. 109 (43.60%) and sitagliptin was found in a minimum number of prescriptions i.e.28 (11.20%) and most of the 
prescriptions contained antihypertensive agents, analgesics, vitamins and minerals preparations as supplements. 
Conclusion: This report alarm all the physicians and health care professionals about various drug interactions and adverse drug reactions which 
occur due to polypharmacy and also causing a more financial burden to chronic disease patients. 
Keywords: Drug utilization, Diabetes, Drug-drug interactions, Adverse drug reactions, DDD-defined daily dosage, ATC-Anatomical Therapeutic 
Chemical Classification and OPD-outpatient department 
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INTRODUCTION 
Diabetes mellitus (DM) is a group of metabolic diseases in which 
there is the elevation of blood sugar levels over a prolonged period 
[1]. High blood sugar cause frequent urination, increased thirst and 
increased hunger. If left untreated, diabetes can cause many 
complications [2]. Acute complications include diabetic ketoacidosis 
and hyperosmolar nonketotic coma [3]. Serious long-term 
complications include cardiovascular disease, stroke, chronic kidney 
failure, foot ulcers, and damage to the eyes [2]. 
As of 2013, 382 million people have diabetes worldwide [4]. Type 2 
makes up about 90% of the cases [5, 6]. This is equal to 8.3% of the 
adult population [4] with equal rates in both women and men [6]. As 
of 2014, an estimated 387 million people have diabetes all over the 
world [7] with type 2 DM making up about 90% of the cases [4, 5]. 
From 2012 to 2014, diabetes is estimated to have resulted in 1.5 to 
4.9 million deaths each year [7]. Diabetes, at least, doubles a 
person's risk of death [3]. The number of people with diabetes is 
expected to rise to 592 million by 2035[7]. The global economic cost 
of diabetes in 2014 was estimated to be $612 billion USD [4].  
The greatest increase in diabetes rates was expected to occur in Asia 
and Africa, where most people with diabetes will probably live in 
2030 [8]. The increase in rates in developing countries follows the 
trend of urbanization and lifestyle changes, including a "Western-
style" diet. 
Drug utilization study is a vital segment of pharmacoepidemiology, 
which describes the amount, quality, and determinants of drug 
exposure with the ultimate goal to facilitate rational use of drugs in 
the population [9–12]. Drug therapy is a major component of patient 
care management in health care settings. Prescribers and consumers 
are flooded with a vast array of pharmaceutical products with 
numerous brand names, available often at an unaffordable cost [13]. 
Irrational and inappropriate use of drugs in health care system 
notice globally is a major concern [9, 14, 15]. In this regard drug 
utilization study was undertaken in the diabetic outpatient clinics in 
urban Telangana state using ATC/defined daily dosage (DDD) 
system. 
MATERIALS AND METHODS 
A prospective observational study was carried out a period of six 
months from various outpatient clinics, hospitals, and pharmacies 
once the consultation by the physician was over, the prescriptions 
were copied, and the patients were interviewed as per the WHO 
guidelines and the following indicators were determined. DDD was 
calculated as per guidelines for ATC classification and DDD 
assignment as given by WHO collaborating center for drug statistics 
methodology, Oslo, Norway. 
• Collect information on the diagnosis, drugs prescribed and 
calculate the mean number of drugs per prescription. 
• Calculate the percentage of drugs prescribed the percentage of 
drugs prescribed by generic name, an average number of 
prescriptions (mean). 
• Analyze the prescriptions for completeness of information as the 
presence of OPD number, name, age, and sex of the patient, 
diagnosis, name, dose, and duration of prescribed drugs. 
• Percentage of drug prescribed from essential drug list or 
formulary.  
Inclusion criteria 
Diabetic patients treating as an outpatient, patients with diabetic & 
other co-morbid diseases with the various age group. 
Exclusion criteria 
Patients are unable to communicate, i.e., patients on ventilators or 
seriously ill patients requiring ICU admissions as well as those 
unwilling to participate were excluded from the study. 
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The DDD/1000/day was calculated as follows:  
DDD 1000  day⁄⁄  
=
Total number of dosage units Prescribed × Strength of each dosage unit × 1000
DDD × Duration of study × Total Sample Size
  
RESULTS 
A total of 250 prescriptions were collected, which contained 1674 
different drugs as included according to the inclusion criteria as 
mentioned above, out of 250 patients 95.2 % patients were type-2 
diabetes and 4.8 % patients were type-1 diabetes. Among the 
prescriptions on an average each prescription contained 6.7 drugs 
which indicate polypharmacy. There were males (55%) than females 
(45%). Most of the prescriptions contained vitamins and minerals 
preparations as supplements. Among the subcategories of anti-
diabetic drugs, Metformin was found in a maximum number of 
prescription i.e. 109 (43.60%) and sitagliptin was found in a 
minimum number of prescriptions, i.e.,.28 (11.20%). There were 
32.1% patients with diabetics are 61 y and above age projected in 
fig.1. The DDD/1000/day and the percentage of drugs prescribed 
were described in the table.1, and the DDD/1000/day maximum 
value was found to be gliclazide. DDD was calculated as per 
guidelines for ATC classification and DDD assignment as given by 
WHO collaborating center for drug statistics methodology, Oslo, 
Norway. 
The prescription pattern of Antidiabetics drugs in a number of 
Prescriptions is shown in fig.2. The types of antidiabetic drugs 
prescribed according to age exhibit in table 2. metformin prescribed 
concomitantly along with other antidiabetic drugs was found more 
often 27.2% of prescriptions(table.5). 36.8 % of prescriptions were 
observed to be prescribed with highest in a number of drugs (8 in 
each) which was reveal in table 6. Only 4.8% of Percent of drugs 
prescribed by generic Name. Whereas the Percentage of drugs 
prescribed from National Essential drug list (NEDL)/National 
Formulary of India (NFI) was 34.18%.  
 
 
Fig. 1: Patients according to the age groups 
 
 
Fig. 2: Types of Antidiabetic drugs prescribed in number of 
prescriptions 
 
Table 1: The DDD/1000/day and the percentage of drugs prescribed at the diabetic OPD clinics 
S. No.  Types of anti-diabetics No. of prescriptions Percentage of usage DDD/1000/day 
1 Metformin (Biguanide) 109 43.60 0.33 
2 Glibenclamide (Sulfonylurea) 34 13.60 0.66 
3 Glipizide (Sulfonylurea) 42 16.80 1.33 
4 Gliclazide (Sulfonylurea) 54 21.60 1.78 
5 Repaglinide (Meglitinide) 32 12.80 0.67 
6 Rosiglitazone (Thiazolidinedione) 51 20.40 0.89 
7 Sitagliptin (Dipeptidyl Peptidase-4 Inhibitors) 28 11.2 0.533 
8 Insulin 45 18.00 0.625 
Total: 6.818 
 
Table 2: Age distribution of prescriptions according to antidiabetic drugs 
Anti-diabetic drugs Age in years 
Drug names ATC codes No. of prescriptions 1-20 y 21-40 y 41-60 y Above 61 y 
Metformin A10BA02 109 12 22 40 35 
Glibenclamide A10BB01 34 02 08 10 14 
Glipizide A10BB07 42 00 05 27 10 
Gliclazide A10BB09 54 05 10 22 17 
Repaglinide A10BX02 32 00 08 14 10 
Rosiglitazone A10BG02 51 00 11 18 22 
Sitagliptin A10BH01 28 00 08 14 06 
Insulin A10AB01  45 00 06 12 27 
 
Table 3: Gender distribution of prescriptions according to antidiabetics 
Anti-diabetics  No. of prescriptions Gender 
Drugs ATC codes Prescriptions (%)  Male Female 
Metformin A10BA02 43.60 (109) 47 62 
Glibenclamide A10BB01 13.60 (34) 14 20 
Glipizide A10BB07 16.80 (42) 23 19 
Gliclazide A10BB09 21.60 (54) 28 26 
Repaglinide A10BX02 12.80 (32) 15 17 
Rosiglitazone A10BG02 20.40 (51) 23 28 
Sitagliptin A10BH01 11.2 (28) 13 15 
Insulin A10AB01  18.00 (45) 28 17 
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Table 4: Diagnosis of patients receiving antidiabetic 
Diagnosis No. of patients % of patients No. of prescriptions 
TYPE-1 12 4.8 12 
TYPE-2  238 95.2 238 
 
Table 5: Number of occasion’s concomitant antidiabetic prescribed in the prescriptions 
Drugs No. of occasions % occasions (out of total prescriptions) 
Metformin 68 27.2 
Glibenclamide 23 9.2 
Glipizide 18 7.2 
Gliclazide 16 6.4 
Repaglinide 19 7.6 
Rosiglitazone 12 4.8 
Sitagliptin 20 8.0 
Insulin 54 21.6 
 
Table 6: Number of drugs per prescription 
No. of drugs per prescription No. of prescriptions No. of drugs % of prescriptions 
1 03 03 1.2 
2 06 12 2.4 
3 08 24 3.2 
4 08 32 3.2 
5 12 60 4.8 
6 40 240 16 
7 81 567 32.4 
8 92 736 36.8 
 
I. Average drugs per Prescription =  
Total number of drugs 





= 6.69 drugs 
Total number of drugs = 1674 
Total number of Prescriptions = 250 
Average drugs per Prescription = 6.696 drugs 
II. Percentage of prescriptions prescribed by generic name 
=
Total number of generic drugs 





× 100 = 4.8% 
 
DISCUSSION 
Drug utilization studies are important for obtaining data about the 
patterns and quality of use, the determinants of drug use, and the 
outcomes of use. The WHO drug use indicators are highly 
standardized and are recommended for inclusion in drug utilization 
studies [17–19]. The present study attempts mainly to describe the 
current prescribing pattern and drug utilization with the WHO core 
prescribing indicators in Outpatient diabetic clinics. For outpatients, 
DDD/1000/day provides a rough estimate of drug consumptions 
[22]. The utilization of Gliclazide was 1.78 DDD/1000/day. Total 
antidiabetic drug consumption in diabetic OPD clinics was 6.818 
DDD/1000/day. 
Most common antidiabetic prescribed were biguanide (metformin). 
The newer antidiabetic–Repaglinide and Sitagliptin accounted for 
the bulk of prescriptions, which followed the global trend towards 
antidiabetic prescribing. Percentages of prescriptions prescribed by 
generic name are very less 4.8% (20).  
However, prescribing drugs by generic name makes the 
therapeutic management economic and rational as it evades 
prescription writing errors and confusion of dispensing of 
different brand names which sound alike and spell similar [21]. 
The doses of antidiabetic were decided upon according to the 
severity of the disease/disorder, starting with low doses and 
titrating upwards or downwards according to the clinical response 
and the patients were kept on regular follow-up. In our study, we 
found that the average drugs per Prescription are 6.696, which is 
polypharmacy.  
Most of the prescriptions contained multivitamins and minerals, 
analgesics and antiulcer drug preparations as supplements. This 
report alarm all the physicians and health care professionals about 
various drug interactions and adverse drug reactions which are 
occurring due to polypharmacy and also causing a more financial 
burden to chronic disease patients.  
It is advice to prescribe the only optimal drug for the respective 
disease conditions. There is need of various drug utilization studies 
should be conducted to rationalize the prescription patron in India, 
and there should be a vigilance who should monitor the 
prescriptions before dispensing and to minimize the ADR, drug 
interactions and decrease the economic burden and also other 
complications in patients.  
Which can be possible only with Clinical pharmacists, so Indian 
ministry of health should avail the service of a clinical pharmacist in 
Indian? Which will save the economy of the country and also prevent 
the morbidity and mortality occur due to irrational drug 
prescriptions?  
CONCLUSION 
Our study in Hyderabad has shown that pharmacists can contribute 
substantially to promote the rational use of medicines, even in 
resource-limited settings. This, of course, requires strong 
collaboration between different institutions and commitments of the 
pharmacists to the cause. Pharmacist medication review, patient 
counseling and telephone follow-up can minimize the Adverse Drug 
Reactions. Medication discrepancies before and after discharge were 
common targets of intervention.  
These efforts must include both studies to understand the best 
methods to reinforce more successfully the appropriate use of 
medications according to accepted guidelines and innovative tools to 
support physician decision making and patient compliance.  
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DM-Diabetes Mellitus, ADR-Adverse Drug Reaction; USD-US Dollar; 
DDD-defined daily dosage; ATC-Anatomical Therapeutic Chemical 
Classification; OPD-outpatient department. 
WHO–world health organization; ICU–intensive care unit; NEDL-
National Essential drug list and NFI-National Formulary of India 
ACKNOWLEDGEMENT  
Authors thank all the patients for their participation and 
cooperation in the study. 
CONFLICT OF INTERESTS  
Conflict of interest declared none. 
REFERENCES  
1. World Health Organization and International Diabetes 
Federation (IDF) Technical Advisory Group, review and update 
the current WHO guidelines on diabetes. WHO, Geneva; 2005. 
2. World Health Organization. Global Health Estimates: Deaths by 
Cause, Age, Sex and Country from 2000 to 2012. Geneva, WHO; 
2014.  
3. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic 
crises in adult patients with diabetes. Diabetes Care 
2009;32:1335–43. 
4. IDF Diabetes atlas. 6th edition. International Diabetes 
Federation; 2013. p. 7. 
5. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, 
Shibuya K, et al. Years lived with disability (YLDs) for 1160 
sequelae of 289 diseases and injuries in 1990–2010 a 
systematic analysis for the global burden of disease study 
2010. Lancet 2015;9859:2163–96. 
6. Cooke DW, Plotnick L. Type 1 diabetes mellitus in 
pediatrics. Pediatr Rev 2008;29:374–84.  
7. The online version of International Diabetes Federation (IDF) 
Diabetes Atlas. Sixth edition; 2013. p. 71-82. 
8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of 
diabetes: Estimates for the year 2000 and projections for 
2030. Diabetes Care 2004;27:1047–53.  
9. World Health Organization (WHO) and International Network 
for Rational Use of Drugs, How to Investigate Drug Use in 
Health Facilities: Selected Drug Use indicators, WHO/ 
DAP/93.1, WHO, Geneva, Switzerland; 1993. 
10. World Health Organization (WHO) International Working 
Group for Drug Statistics Methodology, WHO Collaborating 
Centre for Drug Statistics Methodology, WHO Collaborating 
Centre for Drug Utilization Research and Clinical 
Pharmacological Services, Introduction to Drug Utilization 
Research, WHO, Oslo, Norway; 2003. 
11. World Health Organization, Introduction to Drug Utilization 
Research, WHO, Oslo, Norway; 2003.  
12. D Lee, U Bergman, LB Storm. Ed John Wiley and Sons, 
Chichester, UK. Studies of drug utilization in 
Pharmacoepidemiology; 2005. p. 401–17. 
13. NY Mirza, S Desai, B Ganguly. Prescribing pattern in a pediatric 
out-patient department in Gujarat. Bangladesh J Pharmacol 
2009;4:39–42. 
14. HV Hogerzeil. Promoting rational prescribing: an international 
perspective. Br J Clin Pharmacol 1995;39:1–6. 
15. B Dinesh Kumar, TC Raghuram, G Radhaiah, K Krishnaswamy. 
Profile of drug users in urban and rural India. 
PharmacoEconomics 1995;7:332–46. 
16. R Like, I Francetic, M Bilusic. Benefits of optimization in 
antibiotic use. Coll Antropol 2007;31:241-6. 
17. World Health Organization (WHO) and International Network 
for Rational Use of Drugs, How to Investigate Drug Use in 
Health Facilities: Selected Drug Use indicators, 
WHO/DAP/93.1. WHO, Geneva, Switzerland; 1993. 
18. World health organization (WHO) international working group 
for drug statistics methodology, who is collaborating center for 
drug statistics methodology, who is collaborating center for drug 
utilization research and clinical pharmacological services, 
introduction to drug utilization research, WHO, Oslo, Norway; 
2003. 
19. World Health Organization, Introduction to Drug Utilization 
Research, WHO, Oslo, Norway; 2003. 
20. Ruckmani A. Rational drug use: a remote possibility? Bull Drug 
Health Information 1995;2:20. 
21. M Nehru, K Kohli, B Kapoor, P Sadhotra, V Chopra, R Sharma. Drug 
utilization study in ophthalmology outpatient department of 
government medical college jammu. JK Science 2005;7:149–51. 
22. WHO Collaborating Centre for Drug Statistics Methodology. 
ATC index with DDDs. Oslo: WHO Collaborating Centre for Drug 
Statistics Methodology; 2002. 
 
